| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 53 | 2024 | 918 | 8.660 |
Why?
|
| Tomography, X-Ray Computed | 155 | 2024 | 20556 | 5.310 |
Why?
|
| Lung | 133 | 2024 | 9999 | 4.960 |
Why?
|
| Radiography, Thoracic | 29 | 2024 | 1302 | 4.220 |
Why?
|
| Lung Diseases | 35 | 2023 | 1909 | 4.150 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 16 | 2024 | 515 | 3.160 |
Why?
|
| Bronchiectasis | 6 | 2023 | 139 | 2.620 |
Why?
|
| Magnetic Resonance Imaging | 107 | 2021 | 36401 | 2.380 |
Why?
|
| Pulmonary Embolism | 31 | 2023 | 2568 | 2.230 |
Why?
|
| Lung Neoplasms | 68 | 2024 | 13383 | 2.160 |
Why?
|
| Pulmonary Emphysema | 19 | 2022 | 684 | 2.070 |
Why?
|
| Pulmonary Fibrosis | 9 | 2023 | 505 | 1.890 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 13 | 2024 | 1222 | 1.840 |
Why?
|
| Image Enhancement | 33 | 2021 | 2881 | 1.820 |
Why?
|
| Emphysema | 7 | 2022 | 238 | 1.620 |
Why?
|
| Optic Flow | 2 | 2022 | 13 | 1.560 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 23 | 2023 | 3204 | 1.550 |
Why?
|
| Respiratory Function Tests | 27 | 2024 | 1683 | 1.470 |
Why?
|
| Pulmonary Circulation | 22 | 2007 | 737 | 1.440 |
Why?
|
| Exhalation | 11 | 2019 | 181 | 1.430 |
Why?
|
| Solitary Pulmonary Nodule | 10 | 2018 | 278 | 1.380 |
Why?
|
| Pleural Neoplasms | 7 | 2016 | 609 | 1.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 30 | 2023 | 5319 | 1.220 |
Why?
|
| Pulmonary Artery | 23 | 2023 | 1927 | 1.130 |
Why?
|
| Mucormycosis | 2 | 2018 | 103 | 1.120 |
Why?
|
| Radiographic Image Enhancement | 10 | 2014 | 876 | 1.110 |
Why?
|
| Pleura | 3 | 2017 | 244 | 1.040 |
Why?
|
| Asbestos | 2 | 2017 | 251 | 1.010 |
Why?
|
| Image Processing, Computer-Assisted | 31 | 2019 | 8998 | 1.010 |
Why?
|
| Helium | 6 | 2014 | 119 | 0.960 |
Why?
|
| Pleural Diseases | 3 | 2017 | 137 | 0.940 |
Why?
|
| Pulmonary Ventilation | 9 | 2009 | 372 | 0.940 |
Why?
|
| Mesothelioma | 5 | 2012 | 807 | 0.930 |
Why?
|
| Humans | 375 | 2024 | 760740 | 0.900 |
Why?
|
| Contrast Media | 43 | 2021 | 5305 | 0.890 |
Why?
|
| Radiation Dosage | 9 | 2016 | 1956 | 0.890 |
Why?
|
| Incidental Findings | 5 | 2024 | 697 | 0.880 |
Why?
|
| Diaphragm | 8 | 2021 | 351 | 0.870 |
Why?
|
| Alveolitis, Extrinsic Allergic | 2 | 2021 | 63 | 0.860 |
Why?
|
| Image Interpretation, Computer-Assisted | 12 | 2021 | 3356 | 0.850 |
Why?
|
| Mucin-5B | 9 | 2023 | 148 | 0.830 |
Why?
|
| Pneumonia | 12 | 2020 | 2143 | 0.820 |
Why?
|
| Respiration | 21 | 2019 | 1656 | 0.810 |
Why?
|
| Angiography | 10 | 2010 | 1595 | 0.790 |
Why?
|
| Radiation Protection | 4 | 2016 | 424 | 0.770 |
Why?
|
| X-Rays | 5 | 2022 | 307 | 0.760 |
Why?
|
| Radiography | 14 | 2024 | 6961 | 0.760 |
Why?
|
| Symbiosis | 1 | 2024 | 294 | 0.750 |
Why?
|
| Gadolinium DTPA | 14 | 2012 | 823 | 0.740 |
Why?
|
| Imaging, Three-Dimensional | 14 | 2010 | 4058 | 0.730 |
Why?
|
| Aged | 161 | 2024 | 169092 | 0.710 |
Why?
|
| Xenon Isotopes | 5 | 2014 | 67 | 0.700 |
Why?
|
| Thoracic Diseases | 4 | 2017 | 99 | 0.700 |
Why?
|
| Magnetic Resonance Angiography | 13 | 2004 | 1431 | 0.690 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 285 | 0.680 |
Why?
|
| Aged, 80 and over | 80 | 2024 | 58919 | 0.680 |
Why?
|
| Ventilation-Perfusion Ratio | 9 | 2007 | 117 | 0.660 |
Why?
|
| Smoking | 19 | 2024 | 9054 | 0.660 |
Why?
|
| Pulmonary Edema | 1 | 2022 | 407 | 0.650 |
Why?
|
| Middle Aged | 176 | 2024 | 220603 | 0.640 |
Why?
|
| Oxygen | 16 | 2023 | 4226 | 0.620 |
Why?
|
| Forced Expiratory Volume | 12 | 2022 | 1814 | 0.620 |
Why?
|
| Thymus Gland | 3 | 2015 | 1243 | 0.610 |
Why?
|
| Body Burden | 2 | 2009 | 158 | 0.610 |
Why?
|
| Lung Diseases, Fungal | 2 | 2019 | 125 | 0.610 |
Why?
|
| Patient Care | 1 | 2024 | 621 | 0.600 |
Why?
|
| Artifacts | 11 | 2009 | 1910 | 0.590 |
Why?
|
| Thorax | 6 | 2022 | 555 | 0.590 |
Why?
|
| Respiratory Mechanics | 6 | 2011 | 699 | 0.590 |
Why?
|
| Female | 220 | 2024 | 392203 | 0.580 |
Why?
|
| Male | 207 | 2024 | 360402 | 0.580 |
Why?
|
| Patient Care Management | 1 | 2021 | 302 | 0.580 |
Why?
|
| Respiratory System Abnormalities | 3 | 2022 | 67 | 0.560 |
Why?
|
| Tomography, Spiral Computed | 4 | 2008 | 273 | 0.560 |
Why?
|
| Virus Diseases | 1 | 2023 | 718 | 0.550 |
Why?
|
| Tumor Burden | 13 | 2023 | 1892 | 0.540 |
Why?
|
| Arthritis, Rheumatoid | 9 | 2024 | 3752 | 0.530 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2018 | 45 | 0.520 |
Why?
|
| Sensitivity and Specificity | 38 | 2018 | 14649 | 0.510 |
Why?
|
| Radiology | 6 | 2020 | 2113 | 0.500 |
Why?
|
| Observer Variation | 10 | 2019 | 2607 | 0.500 |
Why?
|
| Herpes Simplex | 1 | 2018 | 465 | 0.490 |
Why?
|
| Adult | 143 | 2024 | 220995 | 0.480 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2006 | 173 | 0.470 |
Why?
|
| Thymus Neoplasms | 4 | 2018 | 274 | 0.470 |
Why?
|
| Diagnostic Imaging | 9 | 2018 | 3527 | 0.440 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2021 | 5672 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 3 | 2021 | 2812 | 0.440 |
Why?
|
| Xenon | 2 | 2012 | 112 | 0.430 |
Why?
|
| Thoracic Neoplasms | 3 | 2021 | 267 | 0.420 |
Why?
|
| Tidal Volume | 5 | 2019 | 488 | 0.410 |
Why?
|
| Computers, Handheld | 2 | 2004 | 210 | 0.410 |
Why?
|
| Retrospective Studies | 49 | 2024 | 80583 | 0.400 |
Why?
|
| Reproducibility of Results | 30 | 2018 | 20077 | 0.400 |
Why?
|
| Artificial Intelligence | 3 | 2022 | 2575 | 0.390 |
Why?
|
| Esophageal Neoplasms | 3 | 2024 | 1657 | 0.380 |
Why?
|
| Movement | 7 | 2019 | 1476 | 0.370 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2010 | 2789 | 0.370 |
Why?
|
| Algorithms | 12 | 2019 | 14024 | 0.360 |
Why?
|
| Cysts | 1 | 2015 | 680 | 0.350 |
Why?
|
| Bronchial Diseases | 3 | 2006 | 150 | 0.340 |
Why?
|
| Early Detection of Cancer | 4 | 2020 | 3196 | 0.340 |
Why?
|
| Neoplasm Staging | 13 | 2021 | 11118 | 0.340 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 658 | 0.330 |
Why?
|
| Antineoplastic Agents | 12 | 2020 | 13635 | 0.330 |
Why?
|
| Tracheal Diseases | 3 | 2005 | 118 | 0.320 |
Why?
|
| Inhalation | 3 | 2013 | 143 | 0.320 |
Why?
|
| Hypertension, Pulmonary | 7 | 2011 | 1582 | 0.310 |
Why?
|
| Disease Progression | 17 | 2024 | 13495 | 0.310 |
Why?
|
| Prevalence | 12 | 2024 | 15702 | 0.300 |
Why?
|
| Traction | 3 | 2023 | 110 | 0.300 |
Why?
|
| Radiometry | 3 | 2014 | 812 | 0.300 |
Why?
|
| Iceland | 4 | 2020 | 184 | 0.290 |
Why?
|
| Molecular Imaging | 2 | 2011 | 814 | 0.280 |
Why?
|
| Quinazolines | 4 | 2016 | 1371 | 0.280 |
Why?
|
| Bronchi | 3 | 2006 | 846 | 0.280 |
Why?
|
| Forecasting | 2 | 2014 | 2924 | 0.260 |
Why?
|
| Diagnosis, Differential | 15 | 2020 | 12966 | 0.260 |
Why?
|
| Pneumonectomy | 2 | 2012 | 1119 | 0.250 |
Why?
|
| Environmental Exposure | 2 | 2018 | 4483 | 0.250 |
Why?
|
| Posture | 5 | 2024 | 956 | 0.250 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 517 | 0.250 |
Why?
|
| Peristalsis | 1 | 2005 | 60 | 0.240 |
Why?
|
| Boston | 3 | 2024 | 9313 | 0.240 |
Why?
|
| Pulmonary Alveoli | 4 | 2007 | 652 | 0.230 |
Why?
|
| Pulmonary Veins | 6 | 2009 | 716 | 0.230 |
Why?
|
| Pattern Recognition, Automated | 2 | 2012 | 994 | 0.230 |
Why?
|
| Bronchial Arteries | 1 | 2004 | 21 | 0.230 |
Why?
|
| Statistical Distributions | 1 | 2004 | 63 | 0.230 |
Why?
|
| Thymus Hyperplasia | 2 | 2014 | 32 | 0.230 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2006 | 1493 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 7873 | 0.230 |
Why?
|
| Phantoms, Imaging | 7 | 2009 | 2518 | 0.230 |
Why?
|
| Incidence | 12 | 2023 | 21339 | 0.220 |
Why?
|
| Equipment Design | 5 | 2020 | 3501 | 0.220 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 2913 | 0.210 |
Why?
|
| Documentation | 1 | 2009 | 896 | 0.210 |
Why?
|
| Positron-Emission Tomography | 6 | 2018 | 6483 | 0.210 |
Why?
|
| Computer Communication Networks | 1 | 2004 | 293 | 0.210 |
Why?
|
| Polymorphism, Genetic | 4 | 2017 | 4242 | 0.210 |
Why?
|
| Survival Analysis | 4 | 2021 | 10072 | 0.200 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15829 | 0.200 |
Why?
|
| Isotopes | 4 | 2014 | 125 | 0.190 |
Why?
|
| Prognosis | 14 | 2024 | 29601 | 0.190 |
Why?
|
| Ossification, Heterotopic | 1 | 2024 | 235 | 0.190 |
Why?
|
| Sarcoidosis | 2 | 2017 | 520 | 0.190 |
Why?
|
| Fibrosis | 3 | 2023 | 2047 | 0.190 |
Why?
|
| Cohort Studies | 22 | 2022 | 41464 | 0.180 |
Why?
|
| Age Factors | 8 | 2021 | 18381 | 0.180 |
Why?
|
| Graves Disease | 8 | 1993 | 238 | 0.180 |
Why?
|
| Pneumonia, Viral | 1 | 2018 | 3209 | 0.180 |
Why?
|
| Polyesters | 1 | 2022 | 371 | 0.180 |
Why?
|
| Noble Gases | 3 | 2007 | 18 | 0.180 |
Why?
|
| Bronchography | 4 | 2010 | 75 | 0.180 |
Why?
|
| Proportional Hazards Models | 8 | 2020 | 12448 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 2 | 2018 | 641 | 0.180 |
Why?
|
| Gastroesophageal Reflux | 2 | 2020 | 821 | 0.180 |
Why?
|
| Statistics as Topic | 5 | 2011 | 2358 | 0.170 |
Why?
|
| Spirometry | 6 | 2021 | 928 | 0.170 |
Why?
|
| Total Lung Capacity | 4 | 2015 | 149 | 0.170 |
Why?
|
| Radiology Information Systems | 1 | 2004 | 529 | 0.170 |
Why?
|
| Thyroid Gland | 16 | 2019 | 1170 | 0.170 |
Why?
|
| Hernia, Hiatal | 1 | 2020 | 90 | 0.170 |
Why?
|
| Radiation Pneumonitis | 1 | 2020 | 102 | 0.160 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 1999 | 28 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 2164 | 0.160 |
Why?
|
| Statistics, Nonparametric | 8 | 2013 | 2851 | 0.160 |
Why?
|
| Probability | 1 | 2024 | 2475 | 0.160 |
Why?
|
| Carcinoma | 2 | 2005 | 2328 | 0.160 |
Why?
|
| Granuloma | 2 | 2018 | 327 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 834 | 0.160 |
Why?
|
| Feasibility Studies | 8 | 2008 | 5239 | 0.160 |
Why?
|
| Systole | 1 | 2001 | 935 | 0.160 |
Why?
|
| Motion | 4 | 2016 | 779 | 0.160 |
Why?
|
| Fourier Analysis | 4 | 2004 | 440 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 9171 | 0.150 |
Why?
|
| Diastole | 1 | 2001 | 781 | 0.150 |
Why?
|
| Airway Obstruction | 6 | 2010 | 661 | 0.150 |
Why?
|
| Lymphoma | 3 | 2016 | 1899 | 0.150 |
Why?
|
| Churg-Strauss Syndrome | 1 | 1999 | 75 | 0.150 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.150 |
Why?
|
| Administration, Inhalation | 6 | 2014 | 1156 | 0.150 |
Why?
|
| Patient Selection | 2 | 2020 | 4237 | 0.150 |
Why?
|
| Models, Animal | 4 | 2007 | 2108 | 0.150 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2015 | 60 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2022 | 423 | 0.150 |
Why?
|
| Internship and Residency | 4 | 2007 | 5878 | 0.150 |
Why?
|
| Asbestosis | 1 | 2017 | 81 | 0.150 |
Why?
|
| Heart Failure | 1 | 2022 | 11670 | 0.150 |
Why?
|
| Immunotherapy | 6 | 2022 | 4642 | 0.150 |
Why?
|
| Exercise Tolerance | 3 | 2012 | 836 | 0.140 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2012 | 379 | 0.140 |
Why?
|
| Predictive Value of Tests | 11 | 2022 | 15250 | 0.140 |
Why?
|
| Iohexol | 3 | 2014 | 204 | 0.140 |
Why?
|
| Immunocompromised Host | 2 | 2019 | 858 | 0.140 |
Why?
|
| Risk Factors | 14 | 2023 | 74128 | 0.140 |
Why?
|
| Risk Adjustment | 1 | 2021 | 600 | 0.140 |
Why?
|
| Coronary Angiography | 2 | 2006 | 4470 | 0.140 |
Why?
|
| Goiter | 4 | 1993 | 87 | 0.140 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2007 | 189 | 0.140 |
Why?
|
| Longitudinal Studies | 8 | 2021 | 14599 | 0.130 |
Why?
|
| Thyroid Neoplasms | 8 | 1993 | 2332 | 0.130 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 693 | 0.130 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 1365 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 5 | 2019 | 5780 | 0.130 |
Why?
|
| Regional Blood Flow | 6 | 2007 | 1496 | 0.130 |
Why?
|
| Calcinosis | 2 | 2003 | 1469 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2021 | 1185 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 6473 | 0.130 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 3873 | 0.130 |
Why?
|
| Young Adult | 13 | 2024 | 59191 | 0.130 |
Why?
|
| Radiopharmaceuticals | 5 | 2014 | 2650 | 0.130 |
Why?
|
| Swine | 9 | 2003 | 5908 | 0.130 |
Why?
|
| Body Weight | 1 | 2006 | 4615 | 0.120 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 376 | 0.120 |
Why?
|
| Risk Assessment | 7 | 2020 | 23974 | 0.120 |
Why?
|
| Self Report | 2 | 2018 | 3727 | 0.120 |
Why?
|
| Lung Injury | 1 | 2019 | 422 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1051 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2016 | 240 | 0.120 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 2007 | 87 | 0.120 |
Why?
|
| Mediastinal Cyst | 1 | 2014 | 29 | 0.120 |
Why?
|
| Lung Volume Measurements | 2 | 2006 | 375 | 0.120 |
Why?
|
| Lung Transplantation | 2 | 2023 | 1310 | 0.110 |
Why?
|
| Pseudolymphoma | 1 | 2014 | 30 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2018 | 2008 | 0.110 |
Why?
|
| Neoplasms | 8 | 2021 | 22131 | 0.110 |
Why?
|
| Prospective Studies | 21 | 2023 | 54364 | 0.110 |
Why?
|
| Vital Capacity | 4 | 2019 | 971 | 0.110 |
Why?
|
| DNA | 2 | 2018 | 7196 | 0.110 |
Why?
|
| Pulmonary Diffusing Capacity | 4 | 2011 | 94 | 0.110 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 309 | 0.110 |
Why?
|
| Linear Models | 6 | 2019 | 5866 | 0.110 |
Why?
|
| Follow-Up Studies | 13 | 2023 | 39062 | 0.110 |
Why?
|
| Trachea | 3 | 2011 | 1089 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 1463 | 0.110 |
Why?
|
| Survival Rate | 7 | 2021 | 12719 | 0.110 |
Why?
|
| Vehicle Emissions | 1 | 2018 | 655 | 0.110 |
Why?
|
| Regression Analysis | 5 | 2016 | 6339 | 0.100 |
Why?
|
| Carcinoma, Papillary | 4 | 1993 | 785 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2023 | 17878 | 0.100 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 587 | 0.100 |
Why?
|
| Autoantibodies | 5 | 2015 | 2115 | 0.100 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2009 | 350 | 0.100 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 750 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 487 | 0.100 |
Why?
|
| Subtraction Technique | 3 | 2012 | 512 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 1125 | 0.100 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 547 | 0.100 |
Why?
|
| Cystic Fibrosis | 2 | 2019 | 1285 | 0.090 |
Why?
|
| Thyroiditis | 2 | 1993 | 86 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2019 | 871 | 0.090 |
Why?
|
| Animals | 27 | 2018 | 168202 | 0.090 |
Why?
|
| Pituitary Gland | 2 | 2007 | 635 | 0.090 |
Why?
|
| Thyroiditis, Suppurative | 1 | 1990 | 7 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 15908 | 0.090 |
Why?
|
| Liver Neoplasms | 7 | 2016 | 4309 | 0.090 |
Why?
|
| Physical Examination | 1 | 2016 | 1254 | 0.090 |
Why?
|
| ROC Curve | 8 | 2017 | 3575 | 0.090 |
Why?
|
| Pneumothorax | 3 | 2004 | 386 | 0.090 |
Why?
|
| Japan | 4 | 2019 | 1372 | 0.090 |
Why?
|
| Receptors, Thyrotropin | 4 | 1994 | 45 | 0.090 |
Why?
|
| Radionuclide Imaging | 9 | 2004 | 1972 | 0.090 |
Why?
|
| Time Factors | 11 | 2021 | 39908 | 0.090 |
Why?
|
| Aortic Diseases | 2 | 2010 | 735 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2022 | 5486 | 0.090 |
Why?
|
| Radiology Department, Hospital | 2 | 2004 | 406 | 0.090 |
Why?
|
| Mutation | 8 | 2021 | 30015 | 0.090 |
Why?
|
| Densitometry | 1 | 2010 | 151 | 0.080 |
Why?
|
| Hypothyroidism | 4 | 1999 | 668 | 0.080 |
Why?
|
| Ultrasonography | 9 | 2002 | 5965 | 0.080 |
Why?
|
| Thyroid Diseases | 4 | 2002 | 386 | 0.080 |
Why?
|
| Aging | 2 | 2021 | 8700 | 0.080 |
Why?
|
| Comorbidity | 3 | 2009 | 10507 | 0.080 |
Why?
|
| Pharyngeal Diseases | 1 | 1990 | 134 | 0.080 |
Why?
|
| Logistic Models | 7 | 2019 | 13248 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 3164 | 0.080 |
Why?
|
| Residual Volume | 2 | 2011 | 41 | 0.080 |
Why?
|
| Family | 1 | 2020 | 3193 | 0.080 |
Why?
|
| Computer Graphics | 1 | 2011 | 340 | 0.080 |
Why?
|
| Gadolinium | 3 | 2003 | 959 | 0.080 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2009 | 112 | 0.080 |
Why?
|
| Age Distribution | 2 | 2006 | 2872 | 0.080 |
Why?
|
| Adolescent | 21 | 2020 | 88247 | 0.080 |
Why?
|
| Fistula | 1 | 1990 | 212 | 0.080 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 12661 | 0.080 |
Why?
|
| Coronary Disease | 1 | 2003 | 5911 | 0.080 |
Why?
|
| Immunoglobulin G | 7 | 1991 | 4533 | 0.080 |
Why?
|
| Gene Expression | 3 | 2023 | 7569 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2004 | 1624 | 0.080 |
Why?
|
| Carbon Isotopes | 1 | 2009 | 458 | 0.080 |
Why?
|
| Perfusion | 4 | 2007 | 1373 | 0.080 |
Why?
|
| Treatment Outcome | 15 | 2023 | 64572 | 0.080 |
Why?
|
| Sirolimus | 1 | 2015 | 1533 | 0.080 |
Why?
|
| Institutional Management Teams | 1 | 2007 | 31 | 0.080 |
Why?
|
| Triage | 1 | 2015 | 984 | 0.070 |
Why?
|
| Iodine | 1 | 2010 | 287 | 0.070 |
Why?
|
| Lymph Nodes | 4 | 2004 | 3461 | 0.070 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2009 | 106 | 0.070 |
Why?
|
| Melanoma | 3 | 2016 | 5696 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2021 | 3533 | 0.070 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 509 | 0.070 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 6345 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 1048 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2020 | 9277 | 0.070 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 9 | 1994 | 34 | 0.070 |
Why?
|
| Collagen Type I | 1 | 2010 | 616 | 0.070 |
Why?
|
| Body Mass Index | 4 | 2015 | 12942 | 0.070 |
Why?
|
| Amyloidosis | 2 | 1991 | 815 | 0.070 |
Why?
|
| Telomere | 2 | 2024 | 942 | 0.070 |
Why?
|
| Physician Executives | 1 | 2007 | 134 | 0.070 |
Why?
|
| Inflammasomes | 1 | 2012 | 526 | 0.070 |
Why?
|
| Fetal Organ Maturity | 1 | 2006 | 83 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2017 | 2630 | 0.070 |
Why?
|
| Obesity | 2 | 2019 | 12934 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 1551 | 0.070 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2010 | 474 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2016 | 2008 | 0.070 |
Why?
|
| Equipment Failure Analysis | 1 | 2009 | 843 | 0.070 |
Why?
|
| Phenotype | 1 | 2024 | 16572 | 0.070 |
Why?
|
| Particulate Matter | 1 | 2018 | 2602 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 1067 | 0.070 |
Why?
|
| Arteriosclerosis | 1 | 2010 | 1056 | 0.070 |
Why?
|
| Acute Disease | 5 | 2018 | 7236 | 0.070 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2015 | 1073 | 0.070 |
Why?
|
| Rodentia | 1 | 2007 | 261 | 0.070 |
Why?
|
| Radiography, Abdominal | 2 | 2024 | 534 | 0.060 |
Why?
|
| Paragonimiasis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2005 | 14 | 0.060 |
Why?
|
| Thyrotropin | 7 | 1991 | 834 | 0.060 |
Why?
|
| Triiodobenzoic Acids | 1 | 2005 | 123 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 5 | 1994 | 101 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2021 | 3801 | 0.060 |
Why?
|
| Thoracic Wall | 1 | 2007 | 202 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 2048 | 0.060 |
Why?
|
| Filtration | 1 | 2006 | 228 | 0.060 |
Why?
|
| Protein Multimerization | 1 | 2010 | 982 | 0.060 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1985 | 52 | 0.060 |
Why?
|
| Cause of Death | 1 | 2016 | 3683 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 20988 | 0.060 |
Why?
|
| Computer Simulation | 3 | 2012 | 6233 | 0.060 |
Why?
|
| Mediastinum | 2 | 2004 | 266 | 0.060 |
Why?
|
| Models, Educational | 1 | 2007 | 373 | 0.060 |
Why?
|
| Mass Screening | 1 | 2021 | 5425 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 15498 | 0.060 |
Why?
|
| Pyridines | 1 | 2016 | 2875 | 0.060 |
Why?
|
| Fetus | 2 | 2006 | 1862 | 0.060 |
Why?
|
| Chronic Disease | 6 | 2019 | 9310 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1008 | 0.060 |
Why?
|
| Sodium Pertechnetate Tc 99m | 2 | 2002 | 54 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 6807 | 0.060 |
Why?
|
| Health Status | 1 | 2018 | 4076 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2637 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2011 | 2635 | 0.060 |
Why?
|
| Spin Labels | 2 | 2003 | 337 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2011 | 1397 | 0.060 |
Why?
|
| Venules | 1 | 2004 | 161 | 0.060 |
Why?
|
| Radionuclide Angiography | 1 | 2004 | 22 | 0.060 |
Why?
|
| Sex Factors | 2 | 2015 | 10549 | 0.060 |
Why?
|
| Arteriovenous Malformations | 2 | 2002 | 396 | 0.060 |
Why?
|
| Air Pollution | 1 | 2018 | 2355 | 0.060 |
Why?
|
| Registries | 3 | 2019 | 8209 | 0.060 |
Why?
|
| Supine Position | 1 | 2024 | 205 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 2 | 2001 | 401 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2009 | 3593 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 2118 | 0.050 |
Why?
|
| Cartilage Diseases | 1 | 2005 | 157 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 2 | 2012 | 2827 | 0.050 |
Why?
|
| Organometallic Compounds | 2 | 1997 | 646 | 0.050 |
Why?
|
| Echo-Planar Imaging | 2 | 1999 | 663 | 0.050 |
Why?
|
| Kinetics | 1 | 2011 | 6370 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 3410 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2004 | 249 | 0.050 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 12043 | 0.050 |
Why?
|
| Hospitalization | 1 | 2023 | 10708 | 0.050 |
Why?
|
| Intubation | 1 | 2003 | 139 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 1376 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 4021 | 0.050 |
Why?
|
| Case-Control Studies | 5 | 2020 | 22153 | 0.050 |
Why?
|
| Safety | 2 | 2007 | 1149 | 0.050 |
Why?
|
| Systems Integration | 1 | 2004 | 426 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2004 | 289 | 0.050 |
Why?
|
| Abdomen | 2 | 2011 | 1128 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2004 | 527 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2021 | 9644 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 3705 | 0.050 |
Why?
|
| Reference Values | 6 | 2003 | 4919 | 0.050 |
Why?
|
| Iodine Radioisotopes | 4 | 1994 | 1031 | 0.050 |
Why?
|
| Remission Induction | 2 | 2019 | 2391 | 0.050 |
Why?
|
| Myocardium | 1 | 2014 | 4725 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 991 | 0.050 |
Why?
|
| Massachusetts | 2 | 2017 | 8835 | 0.050 |
Why?
|
| Magnetics | 2 | 2003 | 597 | 0.050 |
Why?
|
| Phlebography | 1 | 2002 | 326 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 7390 | 0.050 |
Why?
|
| Software | 2 | 2012 | 4432 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 819 | 0.040 |
Why?
|
| Disease Models, Animal | 5 | 2016 | 18220 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Iodized Oil | 2 | 1992 | 10 | 0.040 |
Why?
|
| Pericardium | 1 | 2004 | 664 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 46 | 0.040 |
Why?
|
| Blood Volume | 1 | 2001 | 547 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 26065 | 0.040 |
Why?
|
| Radiography, Interventional | 2 | 2004 | 1120 | 0.040 |
Why?
|
| Leukemic Infiltration | 1 | 2019 | 47 | 0.040 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 197 | 0.040 |
Why?
|
| United States | 7 | 2017 | 72292 | 0.040 |
Why?
|
| Cyclic AMP | 5 | 1990 | 1463 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 166 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 1122 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 11735 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 1061 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 7995 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2013 | 5074 | 0.040 |
Why?
|
| Organ Size | 2 | 2016 | 2252 | 0.040 |
Why?
|
| Models, Biological | 2 | 2012 | 9461 | 0.040 |
Why?
|
| Proteomics | 2 | 2022 | 3836 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1991 | 4512 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2012 | 4937 | 0.040 |
Why?
|
| Biopsy | 1 | 2010 | 6763 | 0.040 |
Why?
|
| Adipose Tissue | 3 | 2019 | 3310 | 0.040 |
Why?
|
| Cadaver | 1 | 2002 | 1358 | 0.040 |
Why?
|
| Recurrence | 4 | 2012 | 8426 | 0.040 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 6403 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 521 | 0.040 |
Why?
|
| Hyperthyroidism | 3 | 1989 | 294 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2003 | 2278 | 0.040 |
Why?
|
| Genomics | 1 | 2014 | 5822 | 0.040 |
Why?
|
| Arteries | 2 | 2001 | 1120 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2003 | 1436 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2009 | 6223 | 0.040 |
Why?
|
| Body Water | 1 | 1999 | 340 | 0.040 |
Why?
|
| Microscopy | 1 | 2003 | 905 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 3798 | 0.040 |
Why?
|
| Meglumine | 2 | 1996 | 143 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10429 | 0.040 |
Why?
|
| Genotype | 3 | 2018 | 12977 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 504 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 2644 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 4910 | 0.040 |
Why?
|
| Cineangiography | 1 | 1996 | 108 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2012 | 3481 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1985 | 2690 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3245 | 0.030 |
Why?
|
| Electrocardiography | 3 | 2001 | 6346 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 596 | 0.030 |
Why?
|
| Microspheres | 1 | 1999 | 782 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1996 | 209 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 1997 | 245 | 0.030 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 9026 | 0.030 |
Why?
|
| Fibroma | 1 | 1997 | 190 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2019 | 341 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 1990 | 2292 | 0.030 |
Why?
|
| Denmark | 1 | 2018 | 770 | 0.030 |
Why?
|
| Immunoglobulins | 2 | 1989 | 850 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2016 | 133 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2015 | 48 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 4252 | 0.030 |
Why?
|
| Causality | 1 | 2021 | 1241 | 0.030 |
Why?
|
| Prednisolone | 1 | 2016 | 324 | 0.030 |
Why?
|
| Gallium Radioisotopes | 2 | 1992 | 195 | 0.030 |
Why?
|
| Triiodothyronine | 4 | 1989 | 493 | 0.030 |
Why?
|
| Prostate | 1 | 2002 | 1773 | 0.030 |
Why?
|
| Walking | 2 | 2012 | 1197 | 0.030 |
Why?
|
| Palliative Care | 1 | 2009 | 3593 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 11458 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2020 | 23415 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 314 | 0.030 |
Why?
|
| Blood Vessels | 1 | 1999 | 1112 | 0.030 |
Why?
|
| Stents | 1 | 2005 | 3177 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 4539 | 0.030 |
Why?
|
| Monocytes | 1 | 2022 | 2565 | 0.030 |
Why?
|
| Methotrexate | 1 | 2019 | 1716 | 0.030 |
Why?
|
| Thymoma | 1 | 2014 | 188 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 960 | 0.030 |
Why?
|
| Technology, Radiologic | 2 | 2007 | 160 | 0.030 |
Why?
|
| Citrates | 1 | 1992 | 133 | 0.030 |
Why?
|
| Palate, Soft | 1 | 1992 | 100 | 0.030 |
Why?
|
| Software Validation | 1 | 2012 | 59 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 4 | 2000 | 1624 | 0.020 |
Why?
|
| Succimer | 1 | 1991 | 31 | 0.020 |
Why?
|
| Organotechnetium Compounds | 1 | 1991 | 129 | 0.020 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 1991 | 84 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 1991 | 111 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 5776 | 0.020 |
Why?
|
| Antibodies | 2 | 1990 | 2413 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2007 | 8473 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2015 | 1635 | 0.020 |
Why?
|
| Chemokines | 1 | 2015 | 954 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 226 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 2057 | 0.020 |
Why?
|
| Bleomycin | 1 | 2012 | 494 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 1995 | 941 | 0.020 |
Why?
|
| Spleen | 1 | 1997 | 2286 | 0.020 |
Why?
|
| Bronchioles | 1 | 2010 | 30 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 943 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 272 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1996 | 2048 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2019 | 2624 | 0.020 |
Why?
|
| Thyroiditis, Subacute | 1 | 1990 | 11 | 0.020 |
Why?
|
| Lasers | 2 | 2007 | 952 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2019 | 2160 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2872 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 2948 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 428 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 1545 | 0.020 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1990 | 186 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 1626 | 0.020 |
Why?
|
| Vaccination | 1 | 2021 | 3370 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 615 | 0.020 |
Why?
|
| Life Style | 1 | 2020 | 3907 | 0.020 |
Why?
|
| Iodides | 1 | 1988 | 40 | 0.020 |
Why?
|
| Fibrinolysis | 1 | 1990 | 331 | 0.020 |
Why?
|
| China | 1 | 2015 | 2374 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2009 | 273 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2419 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1991 | 584 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 3447 | 0.020 |
Why?
|
| Quality of Life | 2 | 2022 | 13359 | 0.020 |
Why?
|
| Thyroxine | 2 | 1989 | 666 | 0.020 |
Why?
|
| Rubidium | 1 | 2007 | 122 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 5304 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1996 | 1297 | 0.020 |
Why?
|
| Adenoma, Bile Duct | 1 | 1987 | 29 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 861 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 1756 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 1878 | 0.020 |
Why?
|
| Partial Pressure | 1 | 2007 | 245 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2010 | 957 | 0.020 |
Why?
|
| Myocardial Contraction | 2 | 1990 | 1515 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2007 | 66 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1988 | 239 | 0.020 |
Why?
|
| Cleft Palate | 1 | 1992 | 589 | 0.020 |
Why?
|
| Oxygen Consumption | 2 | 2007 | 1866 | 0.020 |
Why?
|
| Embolization, Therapeutic | 2 | 2002 | 1418 | 0.020 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 4947 | 0.020 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1988 | 213 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 5493 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 2425 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 2089 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 2689 | 0.020 |
Why?
|
| Lymphography | 1 | 1987 | 188 | 0.020 |
Why?
|
| Temperature | 2 | 2009 | 2224 | 0.020 |
Why?
|
| Liver | 2 | 2019 | 7512 | 0.020 |
Why?
|
| Paragonimus westermani | 1 | 2005 | 2 | 0.020 |
Why?
|
| Alleles | 1 | 2017 | 6861 | 0.020 |
Why?
|
| Bone Density | 1 | 2019 | 3548 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 2495 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1991 | 988 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2017 | 3418 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1992 | 2224 | 0.020 |
Why?
|
| Pregnancy | 6 | 2006 | 29869 | 0.020 |
Why?
|
| Hematuria | 1 | 1986 | 232 | 0.020 |
Why?
|
| Cell Division | 1 | 1992 | 4457 | 0.010 |
Why?
|
| Cell Line | 4 | 1992 | 15577 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2007 | 592 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 2005 | 15609 | 0.010 |
Why?
|
| Mice | 4 | 2016 | 81368 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 11069 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 4110 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2010 | 2925 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2570 | 0.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2004 | 94 | 0.010 |
Why?
|
| Exercise Test | 1 | 2012 | 2127 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1990 | 1154 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6074 | 0.010 |
Why?
|
| Injections | 1 | 2007 | 832 | 0.010 |
Why?
|
| Heart | 1 | 1997 | 4403 | 0.010 |
Why?
|
| Thrombosis | 1 | 2017 | 2942 | 0.010 |
Why?
|
| Ureter | 1 | 1986 | 368 | 0.010 |
Why?
|
| Salmonella typhi | 1 | 1985 | 198 | 0.010 |
Why?
|
| Vasodilation | 1 | 2007 | 962 | 0.010 |
Why?
|
| Gestational Age | 2 | 2006 | 3577 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1986 | 507 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2007 | 1148 | 0.010 |
Why?
|
| Outpatients | 1 | 2011 | 1596 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1986 | 458 | 0.010 |
Why?
|
| Oxygen Radioisotopes | 1 | 2002 | 75 | 0.010 |
Why?
|
| Chest Tubes | 1 | 2003 | 152 | 0.010 |
Why?
|
| Dyspnea | 1 | 2010 | 1347 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 1068 | 0.010 |
Why?
|
| Adenoma | 1 | 1992 | 2159 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 1987 | 606 | 0.010 |
Why?
|
| Bone Neoplasms | 2 | 1991 | 2527 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3514 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1997 | 2909 | 0.010 |
Why?
|
| Exercise | 1 | 2018 | 5886 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 1995 | 2894 | 0.010 |
Why?
|
| Balloon Occlusion | 1 | 2001 | 125 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1997 | 4849 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1985 | 1390 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2004 | 945 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 11107 | 0.010 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1866 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1985 | 2669 | 0.010 |
Why?
|
| Gravitation | 1 | 1999 | 82 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8619 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 3769 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 6188 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2004 | 1812 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 1369 | 0.010 |
Why?
|
| Rabbits | 1 | 1985 | 4770 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2002 | 1575 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5369 | 0.010 |
Why?
|
| Heart Rate | 1 | 1989 | 4181 | 0.010 |
Why?
|
| Rats | 2 | 1991 | 23716 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7403 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1985 | 2202 | 0.010 |
Why?
|
| Thyroidectomy | 2 | 1993 | 908 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2012 | 4785 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2003 | 2422 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1999 | 1150 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1991 | 12759 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 9526 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1995 | 289 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1991 | 4671 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1991 | 9586 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 1986 | 1923 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 22117 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 1991 | 5144 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 8516 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1994 | 1141 | 0.010 |
Why?
|
| Ovary | 1 | 1997 | 959 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1997 | 636 | 0.010 |
Why?
|
| Citric Acid | 1 | 1992 | 123 | 0.010 |
Why?
|
| Palate | 1 | 1992 | 125 | 0.010 |
Why?
|
| Ploidies | 1 | 1992 | 285 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1992 | 221 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 138 | 0.010 |
Why?
|
| Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 1991 | 81 | 0.010 |
Why?
|
| Phonetics | 1 | 1992 | 198 | 0.010 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 1992 | 102 | 0.010 |
Why?
|
| Phonation | 1 | 1992 | 220 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1992 | 232 | 0.010 |
Why?
|
| Pharynx | 1 | 1992 | 432 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 1994 | 476 | 0.010 |
Why?
|
| Cells, Cultured | 3 | 1990 | 18937 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 1990 | 320 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 1990 | 271 | 0.000 |
Why?
|
| Bucladesine | 1 | 1988 | 118 | 0.000 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1988 | 139 | 0.000 |
Why?
|
| Uterine Neoplasms | 1 | 1997 | 1420 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1988 | 366 | 0.000 |
Why?
|
| Vascular Diseases | 1 | 1996 | 1159 | 0.000 |
Why?
|
| Antithyroid Agents | 1 | 1988 | 72 | 0.000 |
Why?
|
| Technetium | 1 | 1988 | 317 | 0.000 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 457 | 0.000 |
Why?
|
| Culture Media | 1 | 1989 | 895 | 0.000 |
Why?
|
| Platelet Count | 1 | 1990 | 780 | 0.000 |
Why?
|
| Sodium Chloride | 1 | 1989 | 586 | 0.000 |
Why?
|
| Fibrinogen | 1 | 1990 | 887 | 0.000 |
Why?
|
| Renal Veins | 1 | 1986 | 102 | 0.000 |
Why?
|
| Biological Assay | 1 | 1988 | 626 | 0.000 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1992 | 955 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1992 | 4845 | 0.000 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1992 | 2821 | 0.000 |
Why?
|
| Asthma | 1 | 2001 | 6234 | 0.000 |
Why?
|
| Societies, Medical | 1 | 1994 | 3901 | 0.000 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1990 | 1400 | 0.000 |
Why?
|
| Child | 2 | 2002 | 80089 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1988 | 10754 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1992 | 11512 | 0.000 |
Why?
|